[144] Humacyte, Inc. SEC Filing
Humacyte, Inc. notice of proposed sale reports an intended sale of 1,100,000 common shares through UBS Financial Services on or about 08/19/2025 on NASDAQ, with an aggregate market value of $1,790,244.50. The filing shows the shares were originally acquired on 08/26/2021 as early-stage investor holdings converted to Humacyte shares when the company went public via a SPAC, and payment for the original acquisition was in cash. The filer also reported sales during the prior three months: 549,360 shares sold on 08/18/2025 for gross proceeds of $997,429. The filing includes the filers representation that no undisclosed material adverse information is known.
Humacyte, Inc. comunica una proposta di vendita relativa a 1.100.000 azioni ordinarie tramite UBS Financial Services, prevista per il 19/08/2025 sul mercato NASDAQ, per un valore di mercato complessivo di $1.790.244,50. La documentazione indica che le azioni erano state inizialmente acquisite il 26/08/2021 come partecipazione da investitori early-stage convertita in azioni Humacyte quando la società è diventata pubblica tramite una SPAC, e che il pagamento originario è avvenuto in contanti. Il dichiarante segnala inoltre vendite nei tre mesi precedenti: 549.360 azioni vendute il 18/08/2025 per proventi lordi di $997.429. La segnalazione include la dichiarazione del dichiarante secondo cui non è a conoscenza di informazioni sfavorevoli materiali non divulgate.
Humacyte, Inc. informa sobre una propuesta de venta de 1.100.000 acciones ordinarias a través de UBS Financial Services, prevista para el 19/08/2025 en NASDAQ, con un valor de mercado agregado de $1.790.244,50. El expediente indica que las acciones se adquirieron originalmente el 26/08/2021 como participaciones de inversores en etapa inicial convertidas en acciones de Humacyte cuando la compañía salió a bolsa mediante una SPAC, y que el pago original se realizó en efectivo. El presentante también reportó ventas en los tres meses anteriores: 549.360 acciones vendidas el 18/08/2025 por ingresos brutos de $997.429. La presentación incluye la manifestación del presentante de que no conoce información adversa material no divulgada.
Humacyte, Inc.는 UBS Financial Services를 통해 1,100,000 보통주를 2025-08-19경 NASDAQ에서 매도할 예정이라고 통지했으며, 총 시가 가치는 $1,790,244.50입니다. 제출서류에 따르면 이 주식은 원래 2021-08-26에 초기 투자자 지분으로 취득되었고, 회사가 SPAC을 통해 상장하면서 Humacyte 주식으로 전환되었으며, 원래 취득 대금은 현금으로 지불되었다고 합니다. 제출자는 또한 최근 3개월 동안의 매도 내역으로 2025-08-18에 549,360주를 매도하여 총수입 $997,429을 확보했다고 보고했습니다. 제출서에는 제출자가 미공개의 중대한 불리한 정보는 없음을 표시하고 있습니다.
Humacyte, Inc. annonce une proposition de vente de 1 100 000 actions ordinaires par l'intermédiaire de UBS Financial Services, prévue aux alentours du 19/08/2025 sur le NASDAQ, pour une valeur de marché agrégée de $1 790 244,50. Le dossier indique que les actions ont été initialement acquises le 26/08/2021 en tant que participations d'investisseurs en phase initiale, converties en actions Humacyte lors de l'introduction en bourse via une SPAC, et que le paiement initial a été effectué en espèces. Le déclarant a également signalé des ventes au cours des trois mois précédents : 549 360 actions vendues le 18/08/2025 pour des produits bruts de $997 429. La déclaration inclut l'affirmation du déclarant qu'il n'a connaissance d'aucune information défavorable matérielle non divulgée.
Humacyte, Inc. meldet einen geplanten Verkauf von 1.100.000 Stammaktien über UBS Financial Services voraussichtlich am 19.08.2025 an der NASDAQ mit einem aggregierten Marktwert von $1.790.244,50. Die Einreichung weist aus, dass die Aktien ursprünglich am 26.08.2021 als Beteiligungen früher Investoren erworben und beim Börsengang der Gesellschaft via SPAC in Humacyte-Aktien umgewandelt wurden; die ursprüngliche Zahlung erfolgte in Bargeld. Der Meldende berichtet außerdem über Verkäufe in den vorangegangenen drei Monaten: 549.360 Aktien verkauft am 18.08.2025 mit Bruttoerlösen von $997.429. Die Einreichung enthält die Erklärung des Meldenden, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
- Planned sale disclosed with broker and market details (UBS, NASDAQ, approximate date 08/19/2025), supporting market transparency
- Acquisition origin disclosed (conversion from early-stage investor in AHAC on 08/26/2021), which clarifies holding history
- Recent sales reported (549,360 shares on 08/18/2025 for $997,429), providing concrete liquidity activity
- Planned sale size is meaningful in absolute terms (1,100,000 shares; aggregate market value $1,790,244.50) and could add supply to the market
- Seller is monetizing a legacy position (converted SPAC shares), which may indicate continued selling by pre-public investors
Insights
TL;DR: Holder plans to sell 1.1M HUMA shares (~0.70% of outstanding) via UBS, after selling ~549K shares one day earlier.
The filing documents a routine Rule 144 notice: a block of 1,100,000 common shares is scheduled for sale through a broker on 08/19/2025. The filer discloses acquisition origin (converted early-stage investor shares from the SPAC transaction, acquired 08/26/2021) and prior recent sales of 549,360 shares on 08/18/2025 for $997,429. The position size relative to reported outstanding shares (158,372,173) is approximately 0.70%, indicating modest potential issuance to the market. This is a disclosure of intent under Rule 144 rather than a corporate operational indicator.
TL;DR: The filing is a compliance disclosure showing a historical investor liquidating converted SPAC-era holdings.
The notice provides required seller information and acquisition provenance: shares trace to an early-stage investor position in AHAC converted at the companys public listing. The signature representation affirms no undisclosed material adverse information is known to the seller. From a governance standpoint, the filing is a standard transparency step supporting orderly secondary market sales; it does not by itself signal corporate governance actions or changes.
Humacyte, Inc. comunica una proposta di vendita relativa a 1.100.000 azioni ordinarie tramite UBS Financial Services, prevista per il 19/08/2025 sul mercato NASDAQ, per un valore di mercato complessivo di $1.790.244,50. La documentazione indica che le azioni erano state inizialmente acquisite il 26/08/2021 come partecipazione da investitori early-stage convertita in azioni Humacyte quando la società è diventata pubblica tramite una SPAC, e che il pagamento originario è avvenuto in contanti. Il dichiarante segnala inoltre vendite nei tre mesi precedenti: 549.360 azioni vendute il 18/08/2025 per proventi lordi di $997.429. La segnalazione include la dichiarazione del dichiarante secondo cui non è a conoscenza di informazioni sfavorevoli materiali non divulgate.
Humacyte, Inc. informa sobre una propuesta de venta de 1.100.000 acciones ordinarias a través de UBS Financial Services, prevista para el 19/08/2025 en NASDAQ, con un valor de mercado agregado de $1.790.244,50. El expediente indica que las acciones se adquirieron originalmente el 26/08/2021 como participaciones de inversores en etapa inicial convertidas en acciones de Humacyte cuando la compañía salió a bolsa mediante una SPAC, y que el pago original se realizó en efectivo. El presentante también reportó ventas en los tres meses anteriores: 549.360 acciones vendidas el 18/08/2025 por ingresos brutos de $997.429. La presentación incluye la manifestación del presentante de que no conoce información adversa material no divulgada.
Humacyte, Inc.는 UBS Financial Services를 통해 1,100,000 보통주를 2025-08-19경 NASDAQ에서 매도할 예정이라고 통지했으며, 총 시가 가치는 $1,790,244.50입니다. 제출서류에 따르면 이 주식은 원래 2021-08-26에 초기 투자자 지분으로 취득되었고, 회사가 SPAC을 통해 상장하면서 Humacyte 주식으로 전환되었으며, 원래 취득 대금은 현금으로 지불되었다고 합니다. 제출자는 또한 최근 3개월 동안의 매도 내역으로 2025-08-18에 549,360주를 매도하여 총수입 $997,429을 확보했다고 보고했습니다. 제출서에는 제출자가 미공개의 중대한 불리한 정보는 없음을 표시하고 있습니다.
Humacyte, Inc. annonce une proposition de vente de 1 100 000 actions ordinaires par l'intermédiaire de UBS Financial Services, prévue aux alentours du 19/08/2025 sur le NASDAQ, pour une valeur de marché agrégée de $1 790 244,50. Le dossier indique que les actions ont été initialement acquises le 26/08/2021 en tant que participations d'investisseurs en phase initiale, converties en actions Humacyte lors de l'introduction en bourse via une SPAC, et que le paiement initial a été effectué en espèces. Le déclarant a également signalé des ventes au cours des trois mois précédents : 549 360 actions vendues le 18/08/2025 pour des produits bruts de $997 429. La déclaration inclut l'affirmation du déclarant qu'il n'a connaissance d'aucune information défavorable matérielle non divulgée.
Humacyte, Inc. meldet einen geplanten Verkauf von 1.100.000 Stammaktien über UBS Financial Services voraussichtlich am 19.08.2025 an der NASDAQ mit einem aggregierten Marktwert von $1.790.244,50. Die Einreichung weist aus, dass die Aktien ursprünglich am 26.08.2021 als Beteiligungen früher Investoren erworben und beim Börsengang der Gesellschaft via SPAC in Humacyte-Aktien umgewandelt wurden; die ursprüngliche Zahlung erfolgte in Bargeld. Der Meldende berichtet außerdem über Verkäufe in den vorangegangenen drei Monaten: 549.360 Aktien verkauft am 18.08.2025 mit Bruttoerlösen von $997.429. Die Einreichung enthält die Erklärung des Meldenden, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen bekannt sind.
FAQ
What does Humacyte (HUMA) Form 144 filed here disclose?
When and how were the shares being sold originally acquired?
Has the filer sold any Humacyte shares recently?
How large is the proposed sale relative to Humacyte's outstanding shares?
Does the filing state any undisclosed material information about Humacyte?
